Tumour Regression After Intravenous Administration of Novel Tumour-targeted NanomedicinesThursday, 11 April 2013 at 16:00 Add to Calendar ▼2013-04-11 16:00:002013-04-11 17:00:00Europe/LondonTumour Regression After Intravenous Administration of Novel Tumour-targeted NanomedicinesNanomedicine 2013 in Barcelona, SpainBarcelona, SpainSELECTBIOenquiries@selectbiosciences.com The possibility of using genes as medicines to treat cancer is limited by the lack of efficacious delivery systems able to selectively deliver genes to tumours. We demonstrated that the intravenous administration of a tumour-targeted dendriplex led to tumour disappearance of 90% of the tested tumours over one month. |